Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof of Concept Study of Eurartesim in Patients with Imported Uncomplicated Plasmodium vivax Malaria
2013-003763-56Phase 2Terminated
- Sponsor
- Leadiant Biosciences
- Start
- Nov 2013
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of dihydroartemisinin in vivax malaria, sponsored by Leadiant Biosciences. Primary endpoint: Uncorrected Adequate Clinical and Parasitological Response (ACPR) at Day 21. Started Nov 2013; status: terminated.
02
Drugs
dihydroartemisinin
03
Conditions
vivax malaria
Beyond the preview
Go deeper on 2013-003763-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003763-56.